Home
Clinical Trials
Study to Evaluate the Efficac...

Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen

NCT ID: NCT01985334

Last Updated: 2019-03-19

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

4389 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-02-14

Study Completion Date

2016-04-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main goal of this study is to evaluate the efficacy and safety of glycopyrronium bromide and indacaterol maleate and glycopyrronium bromide fixed dose combination (FDC) in patients with moderate COPD who switch from their current COPD therapy. This study aims to provide data on how non-exacerbating, but still symptomatic patients with moderate COPD switching from their current COPD treatment to glycopyrronium bromide or indacaterol maleate and glycopyrronium bromide FDC maintain or improve their symptoms. Another purpose of this study is to increase awareness and usage of validated COPD symptoms tools and dyspnea questionnaires in order to facilitate clinical assessment and improve early diagnosis of symptomatic patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation

NCT01712516

Chronic Obstructive Pulmonary Disease (COPD)

COMPLETED PHASE3

A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD

NCT06545500

Chronic Obstructive Pulmonary Disease

COMPLETED PHASE2

A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator

NCT01794780

COPD

COMPLETED PHASE4

Assessment of Switching From Salmeterol/Fluticasone to Indacaterol/Glycopyrronium in a symtomaticCOPD Patient Cohort

NCT02516592

COPD

COMPLETED PHASE4

Efficacy and Safety of Glycopyrrolate Bromide of COPD Patients

NCT02189577

Chronic Obstructive Pulmonary Disease

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The treatment epoch will last 12 weeks. The total duration of the study for each patient is 12 weeks (from randomization) plus 30 days of safety follow-up.

The study has three phases: screening phase (=wash-out period, if required), treatment phase and safety follow-up phase.

Eligible patients will be randomized to either receive glycopyrronium or indacaterol maleate and glycopyrronium bromide fixed dose combination or to remain in their baseline therapy, in an allocation ratio of 3:1 for each cluster (Groups A, B, C, and D), based on their COPD symptoms and baseline treatment:

Group A: Patients treated with any SABA ( Short-acting β2-adrenergic agonist) and/or SAMA (Short-acting muscarinic antagonist) as monotherapy or in free or fixed dose combination (FDC) will be assigned to glycopyrronium or will remain in their baseline therapy (3:1) Group B: Patients treated with any LABA (Long-acting β2-adrenergic agonist) or LAMA (Long-acting muscarinic antagonist) monotherapy and mMRC score =1 point will be assigned to glycopyrronium or will remain in their baseline therapy (3:1) Group C: Patients treated with any LABA and ICS (Inhaled corticosteroid) in free or FDC will be assigned to indacaterol maleate and glycopyrronium bromide fixed dose combination or will remain in their baseline therapy (3:1) Group D: Patients treated with any LABA or LAMA monotherapy and mMRC score \>1 point will be assigned to indacaterol maleate and glycopyrronium bromide fixed dose combination or will remain in their baseline therapy (3:1) Due to low recruitment in Groups A and B that would lead to a significant delay of trial completion, a protocol amendment was made in order to close the recruitment of Groups A and B at the time the randomization in Groups C and D would be completed. Recruitment of the Groups C and D continued as originally planned

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COPD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A1 (any SABA and/or SAMA)

Patients treated with any SABA and/or SAMA as monotherapy or in free or fixed dose combination will be assigned to glycopyrronium or will remain in their baseline therapy (3:1) during 90 days of treatment

Group Type EXPERIMENTAL

Glycopyrronium

Intervention Type DRUG

Glycopyrronium 50 µg capsule for inhalation via SDDPI once per day

SABA

Intervention Type DRUG

Short-acting β2-adrenergic agonist (SABA) as per approved by each country and as prescribed for each patient, used as background therapy

SAMA

Intervention Type DRUG

Short-acting muscarinic antagonist (SAMA) as per approved by each country and as prescribed for each patient, used as background therapy

A2 (glycopyrronium)

Patients treated with any SABA and/or SAMA as monotherapy or in free or FDC at enrollment and randomized to switch in treatment with glycopyrronium (50 μg o.d.)

Group Type EXPERIMENTAL

Glycopyrronium

Intervention Type DRUG

Glycopyrronium 50 µg capsule for inhalation via SDDPI once per day

SABA

Intervention Type DRUG

Short-acting β2-adrenergic agonist (SABA) as per approved by each country and as prescribed for each patient, used as background therapy

LABA

Intervention Type DRUG

Long Acting Beta Agonist (LABA) as per approved by each country and as prescribed for each patient, used as background therapy

SAMA

Intervention Type DRUG

Short-acting muscarinic antagonist (SAMA) as per approved by each country and as prescribed for each patient, used as background therapy

B1 (any LAMA or LABA and mMRC=1)

Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to remain in their baseline treatment with LABA or LAMA

Group Type EXPERIMENTAL

LABA

Intervention Type DRUG

Long Acting Beta Agonist (LABA) as per approved by each country and as prescribed for each patient, used as background therapy

Indacaterol maleate and glycopyrronium bromide

Intervention Type DRUG

Indacaterol maleate and glycopyrronium bromide fixed dose combination (110/50 µg) capsule for inhalation via SDDPI, once a day

LAMA

Intervention Type DRUG

Long Acting Muscarinic Antagonist (LAMA) as per approved by each country and as prescribed for each patient, used as background therapy

ICS

Intervention Type DRUG

Inhaled corticosteroid (ICS) as per approved by each country and as prescribed for each patient, used as background therapy

B2 (glycopyrronium and mMRC=1)

Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to switch in treatment with glycopyrronium (50 μg o.d.)

Group Type EXPERIMENTAL

LABA

Intervention Type DRUG

Long Acting Beta Agonist (LABA) as per approved by each country and as prescribed for each patient, used as background therapy

Indacaterol maleate and glycopyrronium bromide

Intervention Type DRUG

Indacaterol maleate and glycopyrronium bromide fixed dose combination (110/50 µg) capsule for inhalation via SDDPI, once a day

LAMA

Intervention Type DRUG

Long Acting Muscarinic Antagonist (LAMA) as per approved by each country and as prescribed for each patient, used as background therapy

C1 (any LABA and ICS)

Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to remain in their baseline treatment with LABA and ICS in free or FDC

Group Type EXPERIMENTAL

LABA

Intervention Type DRUG

Long Acting Beta Agonist (LABA) as per approved by each country and as prescribed for each patient, used as background therapy

ICS

Intervention Type DRUG

Inhaled corticosteroid (ICS) as per approved by each country and as prescribed for each patient, used as background therapy

C2 (indacaterol/glycopyrronium)

Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.)

Group Type EXPERIMENTAL

LABA

Intervention Type DRUG

Long Acting Beta Agonist (LABA) as per approved by each country and as prescribed for each patient, used as background therapy

ICS

Intervention Type DRUG

Inhaled corticosteroid (ICS) as per approved by each country and as prescribed for each patient, used as background therapy

D1 (any LAMA or LABA and mMRC>1)

Patients treated with any LABA or LAMA monotherapy and mMRC score \>1 point at Visit 1 and randomized to remain their baseline in treatment with LABA or LAMA

Group Type EXPERIMENTAL

LAMA

Intervention Type DRUG

Long Acting Muscarinic Antagonist (LAMA) as per approved by each country and as prescribed for each patient, used as background therapy

D2 (indacaterol/glycopyrronium and mMRC>1)

Patients treated with any LABA or LAMA monotherapy and mMRC score \>1 point at Visit 1 and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.).

Group Type EXPERIMENTAL

LAMA

Intervention Type DRUG

Long Acting Muscarinic Antagonist (LAMA) as per approved by each country and as prescribed for each patient, used as background therapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Glycopyrronium

Glycopyrronium 50 µg capsule for inhalation via SDDPI once per day

Intervention Type DRUG

SABA

Short-acting β2-adrenergic agonist (SABA) as per approved by each country and as prescribed for each patient, used as background therapy

Intervention Type DRUG

LABA

Long Acting Beta Agonist (LABA) as per approved by each country and as prescribed for each patient, used as background therapy

Intervention Type DRUG

Indacaterol maleate and glycopyrronium bromide

Indacaterol maleate and glycopyrronium bromide fixed dose combination (110/50 µg) capsule for inhalation via SDDPI, once a day

Intervention Type DRUG

LAMA

Long Acting Muscarinic Antagonist (LAMA) as per approved by each country and as prescribed for each patient, used as background therapy

Intervention Type DRUG

SAMA

Short-acting muscarinic antagonist (SAMA) as per approved by each country and as prescribed for each patient, used as background therapy

Intervention Type DRUG

ICS

Inhaled corticosteroid (ICS) as per approved by each country and as prescribed for each patient, used as background therapy

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

glycopyrronium bromide

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female adults aged ≥ 40 years
* Patients with moderate COPD according to the GOLD criteria 2013
* Current or ex-smokers who have a smoking history of at least 10 pack years
* Patients with airflow limitation indicated by a postbronchodilator FEV1 ≥50% and \<80% of the predicted normal value and a post-bronchodilator FEV1/FVC \<0.7 at Visit 2. Post- bronchodilator refers to within 10-15 min of inhalation of 400 μg (4x100 μg) of salbutamol
* Patients who, at Visit 1, have been for at least 3 months on a stable dose of one of the following COPD baseline treatments: \*Any SABA monotherapy (such as, but not limited to, salbutamol) \*Any SAMA monotherapy (such as, but not limited to, ipratropium) \*Any SABA and SAMA in free or FDC (such as, but not limited to, salbutamol/ipratropium) \*Any LABA monotherapy (such as, but not limited to, formoterol, salmeterol, indacaterol) \*Any LAMA monotherapy (such as, but not limited to, tiotropium, aclidinium) except glycopyrronium bromide (NVA237) \*Any LABA and ICS in free (ICS such as, but not limited to, beclomethasone, fluticasone) or FDC (such as, but not limited to, salmeterol/fluticasone, formoterol/budesonide).
* Patients with an mMRC score ≥1 at Visit 1.

Exclusion Criteria

* Patients with conditions contraindicated for treatment with, or having a history of reactions/ hypersensitivity to any of the following inhaled drugs or to drugs of similar chemical classes or any component thereof: Anti-cholinergic agents, Long- and short-acting 2-adrenergic agonists, Sympathomimetic amines, Lactose or any of the other excipients of the trial medication.
* Patients with narrow-angle glaucoma or urinary retention, severe renal impairment (history of estimated glomerular filtration rate below 30 ml/min/1.73 m2 within 12 months prior to visit 1), including those with end-stage renal disease requiring dialysis.
* Patients with active/ clinical history of asthma.If the Investigator finds clear and compelling evidence that a patient was misdiagnosed with asthma in the past, then the burden of proof is on the Investigator to properly document this previous misdiagnosis. This documentation must include the rationale for this change in diagnosis including reference to the differential diagnosis that supports this decision.
* Patients with a history of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
* Patients who have a post-bronchodilator FEV1 decrease more than 10% compared to pre-bronchodilator FEV1 result at Visit 2 (see Appendix 5 for details).
* A documented history of \>1 COPD exacerbation requiring treatment with systemic corticosteroids or antibiotics and/or hospitalization in the previous 12 months.
* Patients who have NOT had a COPD exacerbation in the previous 12 months and develop a COPD exacerbation between screening (Visit 1) and (Visit 2) will not be eligible but will be permitted to be re-screened after a minimum of 6 weeks after the resolution of the COPD exacerbation. (Patients suffering an exacerbation between Visit 1 and Visit 2 can only be re-screened in case it is the first one in the previous 12 months. In case this COPD exacerbation has led to an alteration of the patient COPD treatment, before this patient can be re-screened 3 months of stable COPD treatment will be required as described in Inclusion Criterion 6).
* Patients who, in the judgment of the investigator, have a clinically relevant laboratory abnormality or a clinically significant condition such as (but not limited to): \*Unstable ischemic heart disease, left ventricular failure (NYHA Class III \& IV), history of myocardial infarction,arrhythmia (excluding chronic stable atrial fibrillation). Patients with such events not considered clinically significant by the investigator may be considered for inclusion in the study.\*Uncontrolled hypo-or hyperthyroidism, hypokalaemia or hyperadrenergic state. \*Any condition which might compromise patient safety or compliance, interfere with evaluation, or preclude completion of the study
* History of resting QTc (Fridericia preferred, but Bazett acceptable) \>450 msec (male) or \>460 msec (female) within five years before Visit 1.
* Patients who are treated with glycopyrronium bromide (NVA237) at visit 1 are not allowed to be included into the trialPatients on non-selective beta-blockers. Those patients may enter the study after non-selective beta-blocker withdrawal during a 7-day wash-out period.
* Patients receiving any other prohibited COPD-related medications specified in Table 5-2 Prohibited COPD related medications must undergo the required wash-out period prior to Visit 2.
* Patients who are, in the opinion of the investigator known to be unreliable or non-compliant.
* Patients with a body mass index (BMI) of more than 40 kg/m2.
* Use of other investigational drugs within 5 half-lives of enrollment or within 30 days, whichever is longer.
* Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
* Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during dosing of study treatment.

Minimum Eligible Age

40 Years

Maximum Eligible Age

95 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Novartis Pharmaceuticals

Role: STUDY_DIRECTOR

Novartis Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Novartis Investigative Site

Amstetten, , Austria

Site Status

Novartis Investigative Site

Feldkirch, , Austria

Site Status

Novartis Investigative Site

Hallein, , Austria

Site Status

Novartis Investigative Site

Kirchdorf an der Krems, , Austria

Site Status

Novartis Investigative Site

Leoben, , Austria

Site Status

Novartis Investigative Site

Linz, , Austria

Site Status

Novartis Investigative Site

Perg, , Austria

Site Status

Novartis Investigative Site

Salzburg, , Austria

Site Status

Novartis Investigative Site

Wels, , Austria

Site Status

Novartis Investigative Site

Gosselies, BEL, Belgium

Site Status

Novartis Investigative Site

Gozée, BEL, Belgium

Site Status

Novartis Investigative Site

Zichem, BEL, Belgium

Site Status

Novartis Investigative Site

Antwerp, , Belgium

Site Status

Novartis Investigative Site

Balen, , Belgium

Site Status

Novartis Investigative Site

Braine-l'Alleud, , Belgium

Site Status

Novartis Investigative Site

Brussels, , Belgium

Site Status

Novartis Investigative Site

Brussels, , Belgium

Site Status

Novartis Investigative Site

Brussels, , Belgium

Site Status

Novartis Investigative Site

Erpent, , Belgium

Site Status

Novartis Investigative Site

Éghezée, , Belgium

Site Status

Novartis Investigative Site

Geraardsbergen, , Belgium

Site Status

Novartis Investigative Site

Gilly, , Belgium

Site Status

Novartis Investigative Site

Halen, , Belgium

Site Status

Novartis Investigative Site

Hasselt, , Belgium

Site Status

Novartis Investigative Site

Heusy, , Belgium

Site Status

Novartis Investigative Site

Ieper, , Belgium

Site Status

Novartis Investigative Site

Knokke-Heist, , Belgium

Site Status

Novartis Investigative Site

Lebbeke, , Belgium

Site Status

Novartis Investigative Site

Liège, , Belgium

Site Status

Novartis Investigative Site

Maaseik, , Belgium

Site Status

Novartis Investigative Site

Malmedy, , Belgium

Site Status

Novartis Investigative Site

Mechelen, , Belgium

Site Status

Novartis Investigative Site

Melsbroek, , Belgium

Site Status

Novartis Investigative Site

Merksem, , Belgium

Site Status

Novartis Investigative Site

Montegnée, , Belgium

Site Status

Novartis Investigative Site

Natoye, , Belgium

Site Status

Novartis Investigative Site

Paal-Beringen, , Belgium

Site Status

Novartis Investigative Site

Ronse, , Belgium

Site Status

Novartis Investigative Site

Saint-Médard, , Belgium

Site Status

Novartis Investigative Site

Seraing, , Belgium

Site Status

Novartis Investigative Site

Tournai, , Belgium

Site Status

Novartis Investigative Site

Verviers, , Belgium

Site Status

Novartis Investigative Site

Vilvoorde, , Belgium

Site Status

Novartis Investigative Site

Zottegem, , Belgium

Site Status

Novartis Investigative Site

Boskovice, Czech Republic, Czechia

Site Status

Novartis Investigative Site

Brandýs nad Labem, Czech Republic, Czechia

Site Status

Novartis Investigative Site

Brno-Kralovo Pole, Czech Republic, Czechia

Site Status

Novartis Investigative Site

Cvikov, Czech Republic, Czechia

Site Status

Novartis Investigative Site

Havlíčkův Brod, Czech Republic, Czechia

Site Status

Novartis Investigative Site

Jirkov, Czech Republic, Czechia

Site Status

Novartis Investigative Site

Kuřim, Czech Republic, Czechia

Site Status

Novartis Investigative Site

Liberec, Czech Republic, Czechia

Site Status

Novartis Investigative Site

Lovosice, Czech Republic, Czechia

Site Status

Novartis Investigative Site

Neratovice, Czech Republic, Czechia

Site Status

Novartis Investigative Site

Ostrava, Czech Republic, Czechia

Site Status

Novartis Investigative Site

Pardubice, Czech Republic, Czechia

Site Status

Novartis Investigative Site

Pilsen, Czech Republic, Czechia

Site Status